Supernus Pharmaceuticals SUPN Software and Technology Licenses, Net
Software and Technology Licenses, Net at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's software and technology licenses, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's software and technology licenses, net?
- Supernus Pharmaceuticals (SUPN) reported software and technology licenses, net of $56.45M in Q1 2026.
- How has Supernus Pharmaceuticals's software and technology licenses, net changed year-over-year?
- Supernus Pharmaceuticals's software and technology licenses, net increased by 93.2% year-over-year, from $29.22M to $56.45M.
- What is the long-term trend for Supernus Pharmaceuticals's software and technology licenses, net?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's software and technology licenses, net has grown at a 8.1% compound annual growth rate (CAGR), from $43.25M to $63.8M.